Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Dr. Bardwell on Cancer-Related Variables and Depression

      October 25, 2011
      By Wayne A. Bardwell, PhD, MBA
      Article

      Dr. Wayne Bardwell from UCSD Cancer Center on Cancer-Related Variables and Depression

      Wayne A. Bardwell, PhD, MBA, Associate Professor of Psychiatry, director, Patient & Family Support Service, Doris Howell Service Moores, University of California, San Diego, Cancer Center, discusses his research into the connection between objective cancer-related variables and depression symptoms in breast cancer patients.

      The depression symptoms analysis was completed as part of the Women's Healthy Eating and Living (WHEL) study that examined the effects of dietary intervention on 3088 women following the completion of treatment for early-stage breast cancer. Data was collected before and after the introduction of the dietary intervention and tested against 27 potential risk factors that predict depression. Each factor was measured using various instruments that were selected based on social cognitive theory.

      The results of the study were counterintuitive. Objective cancer-related factors, such as intensity of treatment and length of time from diagnosis, as well as health-related factors, such as side effects and physical activity, did not play a role in developing depression. The lead cause of depression stemmed from psychosocial factors such as insomnia, support groups, and being comfortable expressing feelings. These psychosocial issues are very similar to the cause of depression in the general population.

      The trial concluded that depressive symptoms are not associated with objective cancer-related factors but are connected to subjective psychosocial variables.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      4 experts in this video
      4 experts in this video
      4 experts in this video
      4 experts in this video
      Image of a woman with light brown hair wearing glasses with a blue background
      Image of a woman wearing glasses in front of a blue background
      Image of a woman with glasses in front of a blue background
      Image of a man in a suit smiling in front of an Oncology Nursing News background
      Related Content

      Photo of a woman with brown hair and bangs, surrounded by a blue border

      AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

      Michelle Kirschner, RN, MSN, ACNP, APRN-BC
      June 30th 2025
      Article

      Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      Anatomical image of a person with a breast tumor

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      Tim Cortese
      June 11th 2025
      Article

      T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.


      The Vitals

      Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

      Lindsay Fischer
      January 16th 2023
      Podcast

      Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.


      AI-generated graphic of cancer cells

      T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

      Chris Ryan
      June 2nd 2025
      Article

      Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.


      Illustration of two people in lab coats using scientific instruments with a breast icon in the background

      Camizestrant/CDK4/6 Inhibition Boosts PFS in ESR1+ Advanced Breast Cancer

      Caroline Seymour
      June 2nd 2025
      Article

      Camizestrant plus CDK4/6 inhibition improved PFS vs standard care in patients with ER+/HER2– advanced breast cancer and emergent ESR1 mutations.

      Related Content

      Photo of a woman with brown hair and bangs, surrounded by a blue border

      AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

      Michelle Kirschner, RN, MSN, ACNP, APRN-BC
      June 30th 2025
      Article

      Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.


      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

      Lindsay Fischer
      October 2nd 2023
      Podcast

      Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.


      Anatomical image of a person with a breast tumor

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      Tim Cortese
      June 11th 2025
      Article

      T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.


      The Vitals

      Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

      Lindsay Fischer
      January 16th 2023
      Podcast

      Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.


      AI-generated graphic of cancer cells

      T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

      Chris Ryan
      June 2nd 2025
      Article

      Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.


      Illustration of two people in lab coats using scientific instruments with a breast icon in the background

      Camizestrant/CDK4/6 Inhibition Boosts PFS in ESR1+ Advanced Breast Cancer

      Caroline Seymour
      June 2nd 2025
      Article

      Camizestrant plus CDK4/6 inhibition improved PFS vs standard care in patients with ER+/HER2– advanced breast cancer and emergent ESR1 mutations.

      Latest Conference Coverage

      Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC

      No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases

      Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

      Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.